Metformin and resveratrol ameliorate muscle insulin resistance through preventing lipolysis and inflammation in hypoxic adipose tissue

Cellular Signalling

Volumn 28, Issue 9, 2016, Pages 1401-1411

  Zhao, Wenjun ^a   Li, Aiyun ^b,c   Feng, Xin ^a   Hou, Ting ^a   Liu, Kang ^b,c   Liu, Baolin ^b,c   Zhang, Ning ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

^c NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Hypoxia; Insulin resistance; Lipolysis; Metformin; Resveratrol

Indexed keywords

CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; DIACYLGLYCEROL; DIGOXIN; FATTY ACID; GLUCOSE; HORMONE SENSITIVE LIPASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INSULIN; METFORMIN; PHOSPHODIESTERASE III; PIMONIDAZOLE; PROTEIN KINASE C; RESVERATROL; STILBENE DERIVATIVE;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME LOCALIZATION; FATTY ACID TRANSPORT; HYPOXEMIA; INFLAMMATION; INSULIN RESISTANCE; LIPID DIET; LIPID METABOLISM; LIPID STORAGE; LIPOLYSIS; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; 3T3-L1 CELL LINE; ANIMAL; BIOLOGICAL MODEL; COMPLICATION; DRUG EFFECTS; FEEDING BEHAVIOR; HYPOXIA; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; MUSCLE; ORAL DRUG ADMINISTRATION; PATHOLOGY; SIGNAL TRANSDUCTION;

3T3-L1 CELLS; ADIPOSE TISSUE; ADMINISTRATION, ORAL; ANIMALS; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DIET, HIGH-FAT; DIGLYCERIDES; FATTY ACIDS; FEEDING BEHAVIOR; GLUCOSE; HYPOXIA; INFLAMMATION; INSULIN; INSULIN RESISTANCE; LIPOLYSIS; MALE; METFORMIN; MICE; MICE, INBRED ICR; MODELS, BIOLOGICAL; MUSCLES; SIGNAL TRANSDUCTION; STILBENES;

EID: 84976330090     PISSN: 08986568     EISSN: 18733913     Source Type: Journal    
DOI: 10.1016/j.cellsig.2016.06.018     Document Type: Article

References (43)

1. [1] Glass, C.K., Olefsky, J.M., Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab. 15:5 (2012), 635–645.
2. [2] Shu, C.J., Benoist, C., Mathis, D., The immune system's involvement in obesity-driven type 2 diabetes. Semin. Immunol. 24:6 (2012), 436–442.
3. [3] Hosogai, N., Fukuhara, A., Oshima, K., Miyata, Y., Tanaka, S., Segaw, K., Furukawa, S., Tochino, Y., Komuro, R., Matsuda, M., Shimomura, I., Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 56:4 (2007), 901–911.
4. [4] Trayhurn, P., Hypoxia and adipose tissue function and dysfunction in obesity. Physiol. Rev. 93:1 (2013), 1–21.
5. [5] Lee, Y.S., Kim, J.W., Osborne, O., Oh, D.Y., Sasik, R., Schenk, S., et al. Increased adipocyte O2 consumption triggers HIF-1α, causing inflammation and insulin resistance in obesity. Cell 157:6 (2014), 1339–1352.
6. [6] Gastaldelli, A., Morales, M.A., Marraccini, P., Sicari, R., The role of cardiac fat in insulin resistance. Curr. Opin. Clin. Nutr. Metab. Care. 15:6 (2012), 523–528.
7. [7] Lafontan, M., Girard, J., Impact of visceral adipose tissue on liver metabolism. Part I: heterogeneity of adipose tissue and functional properties of visceral adipose tissue. Diabete Metab. 34:4 Pt 1 (2008), 317–327.
8. [8] Kowalski, G.M., De Souza, D.P., Burch, M.L., Hamley, S., Kloehn, J., Selathurai, A., Tull, D., O'Callaghan, S., McConville, M.J., Bruce, C.R., Application of dynamic metabolomics to examine in vivo skeletal muscle glucose metabolism in the chronically high-fat fed mouse. Biochem. Biophys. Res. Commun. 462:1 (2015), 27–32.
9. [9] Lim, S., Meigs, J.B., Links between ectopic fat and vascular disease in humans. Arterioscler. Thromb. Vasc. Biol. 34:9 (2014), 1820–1826.
10. [10] Szendroedi, J., Yoshimura, T., Phielix, E., Koliaki, C., Marcucci, M., Zhang, D., Jelenik, T., Muller, J., Herder, C., Nowotny, P., Shulman, G.I., Roden, M., Role of diacylglycerol activation of PKCθ in lipid-induced muscle insulin resistance in humans. Proc. Natl. Acad. Sci. U. S. A. 111:26 (2014), 9597–9602.
11. [11] Foretz, M., Guigas, B., Bertrand, L., Pollak, M., Viollet, B., Metformin: from mechanisms of action to therapies. Cell Metab. 20:6 (2014), 953–966.
12. [12] Woo, S.L., Xu, H., Li, H., Zhao, Y., Hu, X., Zhao, J., et al. Metformin ameliorates hepatic steatosis and inflammation without altering adipose phenotype in diet-induced obesity. PLoS One, 9(3), 2014, e91111.
13. [13] Sun, Y., Li, J., Xiao, N., Wang, M., Kou, J., Qi, L., Huang, F., Liu, B., Liu, K., Pharmacological activation of AMPK ameliorates perivascular adipose/endothelial dysfunction in a manner interdependent on AMPK and SIRT1. Pharmacol. Res. 89 (2014), 19–28.
14. [14] Grant, P.J., The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. Diabetes Care 19:1 (1996), 64–66.
15. [15] Castro Cabezas, M., van Wijk, J.P., Elte, J.W., Klop, B., Effects of metformin on the regulation of free fatty acids in insulin resistance: a double-blind, placebo-controlled study. J. Nutr. Metab., 2012, 2012, 394623.
16. [16] Zhang, T., He, J., Xu, C., Zu, L., Jiang, H., Pu, S., Guo, X., Xu, G., Mechanisms of metformin inhibiting lipolytic response to isoproterenol in primary rat adipocytes. J. Mol. Endocrinol. 42:1 (2009), 57–66.
17. [17] Ren, T., He, J., Jiang, H., Zu, L., Pu, S., Guo, X., Xu, G., Metformin reduces lipolysis in primary rat adipocytes stimulated by tumor necrosis factor-alpha or isoproterenol. J. Mol. Endocrinol. 37:1 (2006), 175–183.
18. [18] Bagul, P.K., Banerjee, S.K., Application of resveratrol in diabetes: rationale, strategies and challenges. Curr. Mol. Med. 15:4 (2015), 312–330.
19. [19] Côté, C.D., Rasmussen, B.A., Duca, F.A., Zadeh-Tahmasebi, M., Baur, J.A., Daljeet, M., Breen, D.M., Filippi, B.M., Lam, T.K., Resveratrol activates duodenal Sirt1 to reverse insulin resistance in rats through a neuronal network. Nat. Med. 21:5 (2015), 498–505.
20. [20] Riganti, C., Campia, I., Kopecka, J., Gazzano, E., Doublier, S., Aldieri, E., Bosia, A., Ghigo, D., Pleiotropic effects of cardioactive glycosides. Curr. Med. Chem. 18:6 (2011), 872–885.
21. [21] Zhang, H., Qian, D.Z., Tan, Y.S., Lee, K., Gao, P., Ren, Y.R., Rey, S., Hammers, H., Chang, D., Pili, R., Dang, C.V., Liu, J.O., Semenza, G.L., Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth. Proc. Natl. Acad. Sci. U. S. A. 105:50 (2008), 19579–19586.
22. [22] Yoshida, T., Zhang, H., Iwase, T., Shen, J., Semenza, G.L., Campochiaro, P.A., Digoxin inhibits retinal ischemia-induced HIF-1α expression and ocular neovascularization. FASEB J. 24:6 (2010), 1759–1767.
23. [23] Zhao, W., Wang, M., Shao, L., Liao, M., Liu, K., Huang, F., Liu, B., The total phenolic fraction of Anemarrhena asphodeloides inhibits inflammation and reduces insulin resistance in adipocytes via regulation of AMP-kinase activity. Planta Med. 80:2–3 (2014), 146–152.
24. [24] Wang, B., Wood, I.S., Trayhurn, P., Dysregulation of the expression and secretion of inflammation-related adipokines by hypoxia in human adipocytes. Pflugers Arch. 455:3 (2007), 479–492.
25. [25] Rius, J., Guma, M., Schachtrup, C., Akassoglou, K., Zinkernagel, A.S., Nizet, V., Johnson, R.S., Haddad, G.G., Karin, M., NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature 453:7196 (2008), 807–811.
26. [26] Ye, J., Gao, Z., Yin, J., He, Q., Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am. J. Physiol. Endocrinol. Metab. 293:4 (2007), E1118–E1128.
27. [27] W. Zhao, A. Li, X. Feng, T. Hou, K. Liu, B. Liu, N. Zhang, Data on biochemical indexes of HFD-fed mice, Cellular Signalling Data in Brief, (submitted).
28. [28] Blaak, E.E., van Baak, M.A., Kemerink, G.J., Pakbiers, M.T., Heidendal, G.A., Saris, W.H., β-Adrenergic stimulation and abdominal subcutaneous fat blood flow in lean, obese, and reduced-obese subjects. Metabolism 44:2 (1995), 183–187.
29. [29] Kabon, B., Nagele, A., Reddy, D., Eagon, C., Fleshman, J.W., Sessler, D.I., Kurz, A., Obesity decreases perioperative tissue oxygenation. Anesthesiology 100:2 (2004), 274–280.
30. [30] Takiyama, Y., Harumi, T., Watanabe, J., Fujita, Y., Honjo, J., Shimizu, N., Makino, Y., Haneda, M., Tubular injury in a rat model of type 2 diabetes is prevented by metformin: a possible role of HIF-1α expression and oxygen metabolism. Diabetes 60:3 (2011), 981–992.
31. [31] Zheng, J., Ramirez, V.D., Inhibition of mitochondrial proton F0F1-ATPase/ATP synthase by polyphenolic phytochemicals. Br. J. Pharmacol. 130:5 (2000), 1115–1123.
32. [32] Li, X., Li, J., Wang, L., Li, A., Qiu, Z., Qi, L.W., Kou, J., Liu, K., Liu, B., Huang, F., The role of metformin and resveratrol in the prevention of hypoxia-inducible factor 1α accumulation and fibrosis in hypoxic adipose tissue. Br. J. Pharmacol. 173:12 (2016), 2001–2015.
33. [33] Zhu, K.N., Jiang, C.H., Tian, Y.S., Xiao, N., Wu, Z.F., Ma, Y.L., Lin, Z., Fang, S.Z., Shang, X.L., Liu, K., Zhang, J., Liu, B.L., Yin, Z.Q., Two triterpeniods from Cyclocarya paliurus (Batal) Iljinsk (Juglandaceae) promote glucose uptake in 3T3-L1 adipocytes: The relationship to AMPK activation. Phytomedicine 22:9 (2015), 837–846.
34. [34] Hattori, Y., Suzuki, K., Hattori, S., Kasai, K., Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension 47:6 (2006), 1183–1188.
35. [35] Yang, S.J., Lim, Y., Resveratrol ameliorates hepatic metaflammation and inhibits NLRP3 inflammasome activation. Metabolism 63:5 (2014), 693–701.
36. [36] Fain, J.N., Pointer, R.H., Ward, W.F., Effects of adenosine nucleosides on adenylate cyclase, phosphodiesterase, cyclic adenosine monophosphate accumulation, and lipolysis in fat cells. J. Biol. Chem. 247:21 (1972), 6866–6872.
37. [37] Miller, R.A., Chu, Q., Xie, J., Foretz, M., Viollet, B., Birnbaum, M.J., Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 494:7436 (2013), 256–260.
38. [38] Degerman, E., Ahmad, F., Chung, Y.W., Guirguis, E., Omar, B., Stenson, L., Manganiello, V., From PDE3B to the regulation of energy homeostasis. Curr. Opin. Pharmacol. 11:6 (2011), 676–682.
39. [39] Zhang, H.H., Halbleib, M., Ahmad, F., Manganiello, V.C., Greenberg, A.S., Tumor necrosis factor-alpha stimulates lipolysis in differentiated human adipocytes through activation of extracellular signal-related kinase and elevation of intracellular cAMP. Diabetes 51:10 (2002), 2929–2935.
40. [40] Ke, B., Zhao, Z., Ye, X., Gao, Z., Manganiello, V., Wu, B., Ye, J., Inactivation of NF-κB p65 (RelA) in liver improves insulin sensitivity and inhibits cAMP/PKA pathway. Diabetes 64:10 (2015), 3355–3362.
41. [41] Perry, R.J., Samuel, V.T., Petersen, K.F., Shulman, G.I., The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature 510:7503 (2014), 84–91.
42. [42] Ciaraldi, T.P., Aroda, V., Mudaliar, S.R., Henry, R.R., Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment. Metabolism 62:11 (2013), 1587–1596.
43. [43] Szkudelski, T., Szkudelska, K., Resveratrol and diabetes: from animal to human studies. Biochim. Biophys. Acta 1852:6 (2015), 1145–1154.